Español
English
Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas.
Its pharma division is mainly devoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer’s disease.
The diagnostic division develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as the Alzheimer’s disease.
Its service division develops research projects for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area. It offers consultancy services as well.
Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 10 patent applications (2 of them recently granted by the European Union and other 1 in USA) and exclusive platforms for drug discovery and development.
Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.
Neuron and Neol have facilities, laboratories and cutting-edge equipment in the biotechnology field, clean rooms, rodent and zebrafish facilities, and also an own pilot plant for demonstration of the developed processes.
They have a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects, in which the company has already invested over €30 million.
Neuron Bio has facilities in Granada and Madrid that are connected with university research centers and is quoted on the Alternative Stock Market (MAB) in Spain.
